Gilead Sciences, Inc.
Business Model Analysis
How Gilead Sciences Makes Money
Annual Revenue: $29.4B
- How does Gilead Sciences make money?
- Gilead Sciences makes money from HIV, Liver Disease, Oncology and Veklury, Other Products and Royalties.
Gilead Sciences generates revenue primarily through Biotechnology, with roughly $29.4B in annual revenue.
Core Growth Engine: Gilead's growth plan has four parts: expand HIV prevention with Yeztugo and Descovy, defend HIV treatment with next-generation regimens such as bictegravir/lenacapavir, grow liver disease with Livdelzi, and buy into onco...
Revenue Model & Pricing
Gilead discovers, licenses or acquires drug candidates, takes them through clinical trials and regulatory approval, then sells them through wholesalers, pharmacies and hospitals under patent protection. Product sales were $28.9B of FY2025 revenue, with the rest coming from royalties and contract income. HIV is the profit engine: Biktarvy is a once-daily single tablet that patients typically take for years, which makes revenue recurring. Non-GAAP product gross margin was 86.4% in 2025, and Gilead spent $5.8B on R&D plus about $1.0B on acquired in-process R&D. Large acquisitions such as Pharmasset (2011), Kite (2017), Immunomedics (2020), CymaBay (2024) and Arcellx (2026) have supplied most of its new franchises.
Core Revenue Streams
HIV
~71%$20.8B in FY2025 product sales, led by Biktarvy ($14.3B) and Descovy ($2.8B), plus the Yeztugo launch.
Liver Disease
~11%$3.2B in FY2025 from hepatitis C (Epclusa), hepatitis B and D (Vemlidy, Hepcludex) and Livdelzi.
Oncology (Cell Therapy and Trodelvy)
~11%Cell therapy sales of $1.8B (Yescarta and Tecartus) and Trodelvy sales of $1.4B in FY2025.
Veklury, Other Products and Royalties
~7%Veklury sales of $911M, other products, and about $0.5B of royalty, contract and other revenue in FY2025.
Growth Strategy
Gilead's growth plan has four parts: expand HIV prevention with Yeztugo and Descovy, defend HIV treatment with next-generation regimens such as bictegravir/lenacapavir, grow liver disease with Livdelzi, and buy into oncology and inflammation. In 2025 it acquired Interius BioTherapeutics for in vivo CAR-T. In 2026 it closed Arcellx (about $7.8B implied equity value), Tubulis ($3.15B upfront, up to $1.85B in milestones) and Ouro Medicines ($1.675B upfront, with Lakefront) to rebuild its pipeline.
How Gilead Sciences Makes Money: FAQ
What are the primary revenue streams generated by Gilead Sciences?
Gilead Sciences generates revenues primarily from the global commercial sale of patented prescription biopharmaceuticals. Antiviral therapies for HIV represent over 65% to 70% of product sales (led by Biktarvy), supplemented by oncology sales (Yescarta, Tecartus, Trodelvy), viral hepatitis therapies (HCV/HBV), Veklury hospital sales, and royalty licensing revenues.
How does Gilead distribute and sell its pharmaceutical products globally?
Gilead distributes its prescription medications primarily through wholesale pharmaceutical distributors (such as McKesson, AmerisourceBergen/Cencora, and Cardinal Health), specialty pharmacies, hospital buying networks, government health agencies, and international national healthcare systems.
What pricing and access strategies does Gilead deploy across developed and developing nations?
In high-income markets, Gilead prices innovative therapies based on clinical value, life-saving outcomes, and health economic savings. In low- and middle-income countries, Gilead utilizes voluntary generic licensing agreements, tiered pricing structures, and global health access partnerships to supply affordable generic versions to millions in developing regions.
What gross margin profile characterizes Gilead's biopharmaceutical manufacturing model?
Gilead consistently generates exceptional gross profit margins (typically 78% to 86%), driven by highly efficient synthetic small-molecule chemical manufacturing, scalable biologic cell culture facilities, strong patent exclusivity, and premium pricing for life-saving therapeutics.
How does Gilead defend its HIV franchise against patent expirations and generic competition?
Gilead defends its leadership through proactive lifecycle management, developing superior second- and third-generation single-tablet regimens with better safety, resistance, and dosing profiles (transitioning patients from TDF-based Truvada to TAF-based Descovy/Biktarvy, and now to twice-yearly long-acting lenacapavir).
How does Kite Pharma monetize its autologous CAR T-cell therapy platform?
Kite Pharma charges premium one-time treatment prices for Yescarta and Tecartus (typically $400,000+ per patient course), reflecting the complex, individualized vein-to-vein genetic engineering process, curative potential, and elimination of recurring lifelong chemotherapy costs.
What proportion of revenue does Gilead reinvest into research and development (R&D)?
Gilead reinvests a substantial 20% to 25% of total annual revenues into R&D (over $5 billion to $6 billion annually), funding phase 1-3 clinical trials, next-generation ADC oncology combinations, viral cure research, and external corporate biotech collaborations.
How do government healthcare programs and Medicare Part D impact Gilead's net realized prices?
In the United States, statutory rebates and discounts provided to Medicaid, the 340B Drug Pricing Program, the AIDS Drug Assistance Program (ADAP), and Medicare Part D standard benefit designs create a mandatory spread between gross list prices and net realized commercial revenues.
How does Gilead make money?
Gilead generates massive billions from a highly concentrated portfolio of antiviral drugs. For years, their absolute cash cow was Biktarvy, a daily pill that completely suppresses HIV. They also made historic profits by inventing Sovaldi and Harvoni, which actually cured Hepatitis C, though this controversially destroyed their own recurring revenue stream.
Related Companies
Compare Gilead Sciences, Inc. With Competitors
Related Monetization Mechanics
Compare revenue streams, unit economics, and business models
Explore Gilead Sciences
Core profile pages, founders and related research hubs for this company.